Congress Materials – Myasthenia Gravis Foundation of America
2025 MGFA International | May 13-15 | The Hague, The Netherlands
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Composite Response to Nipocalimab, a Novel FcRN Blocker, Based on MG-ADL and Quantitative MG Scores in Patients With Generalized Myasthenia Gravis
Beydoun SR, Ait-Tihyaty M, Turkoz I, Gandhi K, Ramchandren S
Design of a Digital Solution to Improve Myasthenia Gravis Patient Symptom Tracking in Routine Clinical Care
Muppidi S, Alpers J, Anderson AEL, Silvestri N, Streicher N, Pandurangadu A, Jayaraman H, Gupta A, Campbell N, Choudhry Z
Disease burden in patients with generalized Myasthenia Gravis
Silvestri N, Ait-Tihyaty M, Gandhi K, Turkoz I, Daskiran M, Shaddinger BC, Lindenstrom E
Economic burden of Myasthenia Gravis exacerbation and crisis from US payer perspective
Labson D, Cai Q, Gandhi K, Ait-Tihyaty M, Nikolaou A, Kwong WJ
Efficacy of Nipocalimab, a Novel Neonatal Fragment Crystallizable Receptor Blocker, as Measured using Quantitative Myasthenia Gravis Assessment: Findings from the Phase 3 Placebo-Controlled Vivacity-MG3 Study
Ramchandren S, Ait-Tihyaty M, Turkoz I, Gandhi K, Nowak RJ
Identifying risk factors for predicting exacerbation and symptom worsening—a retrospective cohort study of patients with Myasthenia Gravis in the United States
Choudhry Z, Park M, Narayanaswami P, Souayah , Govindarajan R, Kutch M, Zurinaga Gutierrez A, Chekroun Martinot A, Campbell N, Nowak RJ
Long-Term Safety and Efficacy of Nipocalimab in Generalized Myasthenia Gravis: Vivacity-MG3 Open-Label Extension Phase Results
Antozzi C, Vu T, Ramchandren S, Nowak RJ, Farmakidis C, Bril V, De BleeckerJ, Yang H, Minks E, Park JS, Grudniak M, Smilowski M, Sevilla T, Hoffmann S, Sivakumar K, Youssef E, Sanga P, Karcher K, Zhu Y, Sheehan J, Sun H
Long-term Use of Oral Corticosteroids and Overall Survival Among Patients with Myasthenia Gravis: A Nationwide Population-based Study
Cai Q, Gandhi K, Batyrbekova N, Isheden G, Ait-Tihyaty M, Kwong WJ
Mapping out the Patient Journey of Generalized Myasthenia Gravis: Insights and Challenges
Choudhry Z, Jackson L, Campbell N, Shea L, Ramchandren S, Ait-Tihyaty M, Gwathmey KG, Grover K, Malo B
Partnering with Patients and Caregivers to Guide the Development of Impactful Study Engagement Tools in a Generalized Myasthenia Gravis Real World Study
Wright J, Landen M, Ait-Tihyaty M, Rospars B, Sawyer B, Choudhry Z, Shea L
Real-world Treatment Patterns Among Patients with Generalized Myasthenia Gravis
Grover K, Gandhi K, Cloutier M, Coteur G, Zhdanava M, El Khoury A, Boonmak P, Cai Q, Tardif-Samson A, Ait-Thiyaty M, Wang Y, Choudhry Z, Silvestri NJ
Safety Profile of Nipocalimab, a New Neonatal Fragment Crystallizable Receptor Blocker in the Phase 3 VIVACITY Study
Katzberg H, Ait-Tihyaty M,Turkoz I, Gandhi K, Ramchandren S
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.